Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms
Interventions: DRUG: Doxorubicin|BIOLOGICAL: Trastuzumab|DRUG: Cyclophosphamide|DRUG: Paclitaxel|DRUG: Epirubicin|DRUG: Docetaxel|DRUG: Carboplatin|DRUG: Fluorouracil
Sponsor: Washington University School of Medicine
Collaborators: Genentech, Inc.